-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
The anaphylatoxin C5a is core effector of complement activation. C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells. Native C5a contains a large N -linked
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0FDA Advisors Split on New Drug for Vasculitis - 3 year(s) ago
Concerns raised about study design and off-protocol use of steroids
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Avacopan for the Treatment of ANCA-Associated Vasculitis | NEJM - 3 year(s) ago
Original Article from The New England Journal of Medicine — Avacopan for the Treatment of ANCA-Associated Vasculitis
Source: New England Journal of MedicineCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 3The complement C5a-C5aR1 GPCR axis in COVID-19 therapeutics - 4 year(s) ago
The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
Source: Trends in ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Avacopan Superior to Steroids in ANCA Vasculitis - 4 year(s) ago
Greater rates of remission and improved renal function seen with oral C5a receptor antagonist
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet
REVIEW The complement system in antineutrophil cytoplasmic antibody-associated #vasculitis: pathogenic player and therapeutic target: Current Opinion in #Rheumatology https://t.co/Hv6XJZEjHa. #AAV #ANCA #autoimmune #rheum #C5a #Avacopan